HOPA 2024 BCOP Bundle On Demand

UAN# 0465-0000-24-014-H99-P

Presenters:

• Lisa Janssen Carlson, PharmD, BCOP
• Elyse MacDonald, PharmD, MS, BCPS
• Jennifer Murphy, PharmD, BCOP

Learning Objectives:

1. Distinguish how historical occurrences have shaped the conduct of clinical trials in current day
2. Implement site-specific strategies, including trial design, for increased diversity, equity, and inclusion (DEI) in clinical trials
3. Design strategies to mitigate barriers for the implementation of DEI practices at the clinical trial site
4. Analyze the positive impacts of increased diversity in clinical trials
5. Create a plan for pharmacy to implement DEI strategies for patients participating in an oncology clinical trial

UAN# 0465-0000-24-016-H01-P

Presenter:

• Brian Primeaux, PharmD, BCOP

Learning Objectives:

1. Explain the structure and mechanism of action of chimeric antigen receptor (CAR) T-cell therapies
2. Interpret the primary literature on the use of CAR T-cell therapy for the treatment of non-Hodgkin’s lymphoma (NHL) and multiple myeloma (MM)
3. Discuss the role of CAR T-cell therapy in NHL and MM
4. Select the toxicity grade for a patient with cytokine release syndrome associated with CAR T-cell therapy
5. Create an appropriate management plan for a patient with toxicity associated with CAR T-cell therapy

UAN# 0465-0000-24-018-H04-P

Presenters:

• Chelsee Jensen, PharmD, BCOP
• Scott Soefje, PharmD, MBA, BCOP, FCCP, FHOPA

Learning Objectives:

1. Describe the key steps in conducting a financial analysis for cancer drugs
2. Explain how cost should be calculated for use in a cancer drug financial analysis
3. Define key financial information needed when calculating margin, including revenue generated by the different types of reimbursement
4. Outline the steps needed to decide which product should be the “preferred” product based on a financial analysis
5. Summarize the reasons cost and margin should be considered when determining drug therapy

UAN# 0465-0000-24-021-H01-P

Presenter:

• Kelly Fritz, PharmD, BCOP

Learning Objectives:

1. Identify the main differences in adult glioma classifications based on World Health Organization (WHO) 2021 molecular characteristics
2. Explain the role of key molecular markers in glioma diagnosis, treatment, and overall prognosis
3. Apply the updated glioma classifications to historical treatment regimens in a patient case
4. Analyze recent clinical trial updates in the treatment of gliomas

UAN# 0465-0000-24-023-H01-P

Presenters:

• Justin Arnall, PharmD, BCOP
• Binni Kunvarjee, PharmD, BCOP

Learning Objectives:

1. Explain the role of the complement system and how therapeutic complement inhibition treats select complement-mediated hemolytic disorders
2. Examine the efficacy of complement inhibition as first-line therapy for atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH)
3. Identify considerations for initial complement inhibitor treatment selection and factors necessitating a change in therapeutic approach for aHUS and PNH
4. Analyze the efficacy of complement inhibition as adjunctive therapy for cold agglutinin disease
5. Outline the role of the pharmacist and drug-specific considerations in facilitating administration of complement inhibitor therapy in inpatient and outpatient settings

UAN# 0465-0000-24-025-H01-P

Presenter:

• Tara Higgins, PharmD, BCPPS, FPPA, FFSHP

Learning Objectives:

1. Summarize the current use of precision medicine in pediatric solid tumors
2. Explain the future use of targeted therapies in select pediatric solid tumors
3. Analyze advantages and disadvantages of utilizing commercially available targeted therapies within the pediatric solid tumor population
4. Apply precision medicine to patient cases

UAN# 0465-0000-24-027-H01-P

Presenter:

• Christine Barrett, PharmD, BCOP

Learning Objectives:

1. Review current guidelines for the treatment of recurrent and metastatic head and neck cancers
2. Interpret the latest data in recurrent and metastatic head and neck cancer
3. Recommend appropriate treatment for recurrent and metastatic head and neck cancer based on patient- and disease-specific factors
4. Discuss ongoing clinical trials for systemic therapy in head and neck cancer